Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Role of Fcγ receptors in HER2-targeted breast cancer therapy

(2022) Antonino Musolino et al.   Journal for ImmunoTherapy of Cancer

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

(2021) Hope S. Rugo et al.   JAMA Oncology

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

(2017) Patrick G. Gavin et al.   JAMA Oncology

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

(2016) A Musolino et al.   PHARMACOGENOMICS JOURNAL

Association Studies of Fc  Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

(2014) N. Norton et al.   Cancer Immunology Research

Analysis of Fc  Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

(2012) S. A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

(2010) K. Tamura et al.   ANNALS OF ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY